- Home
- NXTC vs RLYB Comparison
NXTC vs RLYB Comparison
Compare NXTC & RLYB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NXTC
- RLYB
- Stock Information
- Founded
- NXTC 2015
- RLYB 2018
- Country
- NXTC United States
- RLYB United States
- Employees
- NXTC N/A
- RLYB N/A
- Industry
- NXTC Biotechnology: Pharmaceutical Preparations
- RLYB Biotechnology: Pharmaceutical Preparations
- Sector
- NXTC Health Care
- RLYB Health Care
- Exchange
- NXTC Nasdaq
- RLYB Nasdaq
- Market Cap
- NXTC 13.9M
- RLYB 14.4M
- IPO Year
- NXTC 2019
- RLYB 2021
- Fundamental
- Price
- NXTC $6.17
- RLYB $0.50
- Analyst Decision
- NXTC Strong Buy
- RLYB Hold
- Analyst Count
- NXTC 3
- RLYB 3
- Target Price
- NXTC $33.00
- RLYB $15.00
- AVG Volume (30 Days)
- NXTC 299.6K
- RLYB 8.4M
- Earning Date
- NXTC 08-04-2025
- RLYB 08-07-2025
- Dividend Yield
- NXTC N/A
- RLYB N/A
- EPS Growth
- NXTC N/A
- RLYB N/A
- EPS
- NXTC N/A
- RLYB N/A
- Revenue
- NXTC N/A
- RLYB $848,000.00
- Revenue This Year
- NXTC N/A
- RLYB N/A
- Revenue Next Year
- NXTC N/A
- RLYB N/A
- P/E Ratio
- NXTC N/A
- RLYB N/A
- Revenue Growth
- NXTC N/A
- RLYB N/A
- 52 Week Low
- NXTC $2.69
- RLYB $0.22
- 52 Week High
- NXTC $20.76
- RLYB $1.54
- Technical
- Relative Strength Index (RSI)
- NXTC 62.21
- RLYB 61.32
- Support Level
- NXTC $4.75
- RLYB $0.42
- Resistance Level
- NXTC $5.23
- RLYB $0.54
- Average True Range (ATR)
- NXTC 0.56
- RLYB 0.07
- MACD
- NXTC 0.10
- RLYB 0.01
- Stochastic Oscillator
- NXTC 86.74
- RLYB 56.61
About NXTC NextCure Inc.
NextCure Inc is a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. The company's product candidates include; NC410 a fusion protein of LAIR-2, a fusion protein that, in combination with pembrolizumab, demonstrated early evidence of clinical activity in colorectal (CRC) and ovarian cancers, and LNCB74, an ADC that is directed to B7-H4, a clinically validated cancer target. The company is also seeking a partner for its other clinical programs such as NC525 and NC318 and its preclinical non-oncology programs NC605, for chronic bone diseases and NC181, for Alzheimer's disease.
About RLYB Rallybio Corporation
Rallybio Corp is a clinical stage biotechnology company committed to identifying and accelerating the development of life-transforming therapies for patients with severe and rare disorders. The programs of the company are for the prevention of fetal and neonatal alloimmune thrombocytopenia, a potentially life-threatening rare disease that can cause uncontrolled bleeding in fetuses and newborns.